CCXI Stock Analysis

CCXI -  USA Stock  

USD 13.51  0.02  0.15%

The big decline in price over the last few months for Chemocentryx could raise concerns from stockholders as the firm it trading at a share price of 13.51 on 8,398,000 in volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Chemocentryx or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 10.12. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Chemocentryx partners.
Continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Chemocentryx stock analysis report makes it easy to digest most publicly released information about Chemocentryx and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. CCXI stock analysis module also helps to analyze the Chemocentryx price relationship with some important fundamental indicators such as market cap and management efficiency.

CCXI Stock Analysis Notes

About 24.0% of the company shares are held by company insiders. The book value of Chemocentryx was currently reported as 5.18. The company recorded a loss per share of 0.94. Chemocentryx had not issued any dividends in recent years. ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California. Chemocentryx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. For more info on Chemocentryx please contact Thomas Schall at 650 210-2910 or go to www.chemocentryx.com.

Chemocentryx Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Chemocentryx's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Chemocentryx or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Chemocentryx generates negative expected return over the last 90 days
Chemocentryx has high historical volatility and very poor performance
The company reported the previous year's revenue of 69.24 M. Net Loss for the year was (63.38 M) with loss before overhead, payroll, taxes, and interest of (12.99 M).
Chemocentryx currently holds about 376.28 M in cash with (75.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39.
Chemocentryx has a frail financial position based on the latest SEC disclosures
Over 82.0% of the company shares are held by institutions such as insurance companies
Latest headline from pennsylvanianewstoday.com: Investor Deadline Alerts Kessler Topaz Meltzer Check, LLP, ChemoCentryx, Inc. Reminds Investors of Securities Fraud Class Actions Filed Against Around the Web-Pennsylvania - Pennsylvanianewstoday.com

Chemocentryx Upcoming and Recent Events

Earnings reports are used by Chemocentryx to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Chemocentryx previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of August 2021
Next Earnings Report8th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

CCXI Largest EPS Surprises

Earnings surprises can significantly impact Chemocentryx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-08-08
2017-06-30-0.17-0.19-0.0211 
2018-11-08
2018-09-30-0.2453-0.220.025310 
2019-05-06
2019-03-31-0.2563-0.230.026310 
View All Earnings Estimates

Chemocentryx SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Chemocentryx prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Chemocentryx investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Chemocentryx specific information freely available to individual and institutional investors to make a timely investment decision.
9th of June 2021
Unclassified Corporate Event
View
24th of May 2021
Submission of Matters to a Vote of Security Holders
View
7th of May 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
29th of April 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
8th of March 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
3rd of March 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
1st of March 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
16th of February 2021
Unclassified Corporate Event
View

Chemocentryx Thematic Classifications

In addition to having Chemocentryx stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters IdeaCancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

CCXI Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Chemocentryx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Chemocentryx backward and forwards among themselves. Chemocentryx's institutional investor refers to the entity that pools money to purchase Chemocentryx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares10.4 M535 M
Wellington Management Group LlpCommon Shares6.1 M313.1 M
Blackrock IncCommon SharesM255 M
Vanguard Group IncCommon Shares4.9 M249.5 M
Ra Capital Management LpCommon Shares3.6 M182.3 M
State Street CorpCommon Shares1.8 M92.6 M
Timessquare Capital Management LlcCommon Shares1.5 M79.3 M
Note, although Chemocentryx's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

CCXI Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 923.48 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Chemocentryx's market, we take the total number of its shares issued and multiply it by Chemocentryx's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

CCXI Profitablity

Chemocentryx's profitability indicators refer to fundamental financial ratios that showcase Chemocentryx's ability to generate income relative to its revenue or operating costs. If, let's say, Chemocentryx is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Chemocentryx's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Chemocentryx's profitability requires more research than a typical breakdown of Chemocentryx's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (91.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (90.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.9.
Last ReportedProjected for 2021
Return on Investment(22.26) (24.01) 
Return on Average Assets(0.12) (0.13) 
Return on Average Equity(0.17) (0.19) 
Return on Invested Capital(0.16) (0.18) 
Return on Sales(0.81) (0.87) 

Management Efficiency

The entity has return on total asset (ROA) of (11.2) % which means that it has lost $11.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (30.1) %, meaning that it created substantial loss on money invested by shareholders. Chemocentryx management efficiency ratios could be used to measure how well chemocentryx manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -24.01. The current Return on Average Assets is estimated to decrease to -0.13. Chemocentryx Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 77.33 Million. The current Revenue to Assets is estimated to increase to 0.18, while Return on Average Assets are projected to decrease to (0.13) .
Last ReportedProjected for 2021
Book Value per Share 5.87  5.30 
Enterprise Value over EBIT(81.00) (83.13) 
Enterprise Value over EBITDA(85.85) (88.11) 
Price to Book Value 11.11  12.74 
Tangible Assets Book Value per Share 7.90  7.31 
Enterprise Value4.3 B4.6 B
Tangible Asset Value518.9 M559.9 M

Technical Drivers

As of the 19th of June, Chemocentryx shows the mean deviation of 4.48, and Risk Adjusted Performance of (0.08). Chemocentryx technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Chemocentryx, which can be compared to its rivals. Please confirm Chemocentryx standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Chemocentryx is priced correctly, providing market reflects its regular price of 13.51 per share. Given that Chemocentryx has jensen alpha of (1.32), we suggest you to validate Chemocentryx's prevailing market performance to make sure the company can sustain itself at a future point.

Chemocentryx Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Mid-point over period is an average of Chemocentryx highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Chemocentryx Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chemocentryx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chemocentryx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Chemocentryx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Chemocentryx Predictive Daily Indicators

Chemocentryx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Chemocentryx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Chemocentryx Forecast Models

Chemocentryx time-series forecasting models is one of many Chemocentryx's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Chemocentryx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Chemocentryx Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Chemocentryx stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CCXI shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Chemocentryx. By using and applying CCXI Stock analysis, traders can create a robust methodology for identifying CCXI entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(97.78) (100.36) 
EBITDA Margin(0.77) (0.83) 
Gross Margin 0.90  0.89 
Profit Margin(0.85) (0.92) 
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California. Chemocentryx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.

Current CCXI Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CCXI analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CCXI analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
27.33Hold6Odds
Chemocentryx current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most CCXI analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CCXI stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Chemocentryx, talking to its executives and customers, or listening to CCXI conference calls.
CCXI Analyst Advice Details

CCXI Stock Analysis Indicators

Chemocentryx stock analysis indicators help investors evaluate how Chemocentryx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Chemocentryx shares will generate the highest return on investment. By understating and applying Chemocentryx stock analysis, traders can identify Chemocentryx position entry and exit signals to maximize returns.
Quick Ratio7.06
Fifty Two Week Low9.53
Revenue Growth72.30%
Shares Short Prior Month3.75M
Average Daily Volume Last 10 Day4.07M
Average Daily Volume In Three Month2.84M
Shares Percent Shares Out5.10%
Gross Margins-18.42%
Short Percent Of Float7.55%
Forward Price Earnings-7.40
Float Shares48.73M
Fifty Two Week High70.29
Enterprise Value To Ebitda-25.18
Fifty Day Average18.30
Two Hundred Day Average48.01
Enterprise Value To Revenue22.40
Continue to Trending Equities. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Equity Search
Search for activelly-traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
The market value of Chemocentryx is measured differently than its book value, which is the value of CCXI that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.